Zydus Life Science Quarterly Results for Trading Insights
In Mar 2026, Zydus Life Science (ZYDUSLIFE) reported revenue ₹7,569 Cr and net profit ₹1,341 Cr — revenue +18.8% YoY. Browse ZYDUSLIFE complete financial statements for revenue, profit, balance sheet and cash flow data.
ZYDUSLIFE Quarterly Results — Revenue, Profit & EPS Highlights
Zydus Life Science latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit Zydus Life Science screener.
- Revenue of ₹7,569 Cr in Mar 2026 (+23.1% vs Sept 2025, +18.8% vs Mar 2025)
- Net Profit of ₹1,341 Cr in Mar 2026 (+8.2% vs Sept 2025, +7.8% vs Mar 2025)
- EBITDA of ₹2,139 Cr in Mar 2026 (+6.7% vs Sept 2025)
- Operating Margin of 27.0% in Mar 2026 (-4.0pp vs Sept 2025)
- Earnings Per Share of ₹12.65 in Mar 2026 (+1.1% vs Sept 2025)
Zydus Life Science Quarterly Results — Revenue, EBITDA, Net Profit & EPS
ZYDUSLIFE quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 7,569 | 6,147 | 6,371 | 6,622 | 6,892 | 23.1% | 18.8% |
| Net Profit (₹ Cr) | 1,341 | 1,239 | 1,244 | 1,521 | 1,023 | - | - |
| EBITDA (₹ Cr) | 2,139 | 2,005 | 1,749 | 2,137 | 1,759 | - | - |
| EPS (₹) | 12.65 | 12.51 | 11.64 | 14.58 | 10.36 | - | - |
| Operating Margin (%) | 27.0% | 31.0% | 27.0% | 31.0% | 24.0% | - | - |
ZYDUSLIFE Share Price Trend — 1-Year Movement Across Quarterly Results
Zydus Life Science 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Also explore ZYDUSLIFE price movement history to track price trends across different timeframes.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
ZYDUSLIFE vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Zydus Life Science latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹469,405.89 Cr | 1941.1 | 15,018 | 2,710 | +1.0% | +11.8% | 18.0% | 171.8 |
|
Divis Laboratories
Mar 2026 |
₹194,269.91 Cr | 7248.5 | 2,986 | 751 | +4.4% | +11.8% | 25.2% | 256.0 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹191,454.40 Cr | 4961.5 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 431.1 |
|
Cipla
Mar 2026 |
₹114,318.19 Cr | 1410.6 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 205.3 |
|
Lupin
Mar 2026 |
₹110,051.30 Cr | 2370.5 | 7,533 | 1,469 | +8.8% | +34.1% | 19.5% | 68.1 |
All amounts in ₹ Crores